RT Journal Article
SR Electronic
T1 Convalescent Plasma in Critically ill Patients with Covid-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.11.21258760
DO 10.1101/2021.06.11.21258760
A1 The REMAP-CAP Investigators
A1 Lise J. Estcourt
YR 2021
UL http://medrxiv.org/content/early/2021/06/13/2021.06.11.21258760.abstract
AB BACKGROUND The evidence for benefit of convalescent plasma for critically ill patients with Covid-19 is inconsistent. We hypothesized that convalescent plasma would improve outcomes for critically ill adult patients with Covid-19.METHODS In an ongoing adaptive platform trial, critically ill patients with confirmed Covid-19, defined as receiving intensive care-level organ support, were randomized to open-label convalescent plasma or not (i.e., control group). The primary end point was organ support-free days (i.e., days alive and free of ICU-based organ support) up to day 21. The primary analysis was a Bayesian cumulative logistic model with predefined criteria for superiority or futility. An odds ratio greater than 1 represented improved survival, more organ support–free days, or both.RESULTS The convalescent plasma intervention was stopped after pre-specified criteria for futility were met. At that time, 1084 participants had been randomized to convalescent plasma and 916 to no convalescent plasma (control). The median organ support-free days were 0 (interquartile range, -1 to 16) for the convalescent plasma group and 3 (interquartile range, -1 to 16) days for the control group. The median adjusted odds ratio (OR) was 0.97 (95% credible interval 0.83 to 1.15) and posterior probability of futility (OR < 1.2) was 99.4% for convalescent plasma compared to control. In-hospital mortality was 37.3% (401/1075) in convalescent plasma group, and 38.4% (347/904) in controls. The observed treatment effects were consistent across primary and secondary outcomes.CONCLUSIONS In critically ill adults with confirmed Covid-19, treatment with convalescent plasma, did not improve clinical outcomes.Clinicaltrials.gov: NCT02735707Competing Interest StatementDr Estcourt has received funding from the National Institute for Health Research (UKRIDHSC COVID-19 Rapid Response Rolling Call, 'The use of convalescent plasma to treat hospitalised and critically ill patients with COVID-19 disease' (COV19-RECPLAS)Clinical TrialNCT02735707Clinical Protocols https://www.remapcap.org/protocol-documents Funding StatementThe Platform for European Preparedness Against (Re-) emerging Epidemics (PREPARE) consortium by the European Union, FP7-HEALTH-2013-INNOVATION-1 (#602525), the Australian National Health and Medical Research Council (#APP1101719), the Australian Medical Research Future Fund (#APP2002132); the New Zealand Health Research Council (#16/631), the Canadian Institutes of Health Research COVID-19 Rapid Research Funding Grant (#447335), the Canadian Institute of Health Research Strategy for Patient-Oriented Research Innovative Clinical Trials Program Grant (#158584), the National Institute for Health Research (UKRIDHSC COVID-19 Rapid Response Rolling Call, 'The use of convalescent plasma to treat hospitalised and critically ill patients with COVID-19 disease' (COV19-RECPLAS), the UK National Institute for Health Research (NIHR) and the NIHR Imperial Biomedical Research Centre, the Health Research Board of Ireland (CTN 2014-012), the UPMC Learning While Doing Program, the Translational Breast Cancer Research Consortium, the Pittsburgh Foundation, the French Ministry of Health (PHRC-20-0147), the Minderoo Foundation, and the Wellcome Trust Innovations Project (215522). Australian governments fund Australian Red Cross Lifeblood for the provision of blood products and services to Australia. Collection of UK plasma was funded by the DHSC through core funding under COVID-19 and EU SoHo Grants.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics and regulatory approval were obtained at each of the participating centres in this platform trial. Ethical oversight and approval for the platform was provided by the institutional review board of Monash University, Australia (REMAP-CAP).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available to researchers on request subject to sponsor restrictions from 1-12-2022. Please contact info{at}remapcap.org